A recent government-funded study has revealed that medications originally developed for obesity treatment may also influence cravings beyond food. The research, conducted over two months with 48 adult participants, adds to the growing body of evidence suggesting that GLP-1 receptor agonists like Ozempic and Wegovy could help regulate compulsive behaviors. Published in JAMA Psychiatry, the study was supported by the National Institute on Alcohol Abuse and Alcoholism, a division of the National Institutes of Health. Scientists focused on semaglutide, a drug that mimics gut and brain hormones to regulate appetite and satiety. This mechanism has prompted further investigations into its effects on behavioral patterns associated with dependency, including smoking and excessive consumption of certain substances. Dr. Klara Klein from the University of North Carolina at Chapel Hill noted that many patients taking these medications reported a substantial reduction in cravings.

Participants, all exhibiting tendencies toward compulsive consumption but not actively seeking treatment, were initially observed in a controlled setting. They were then randomly assigned to receive either a weekly semaglutide injection or a placebo. Over nine weeks, behavioral patterns and cravings were monitored, with a final laboratory test conducted at the study’s conclusion. Findings indicated that nearly 40% of those receiving semaglutide reported a significant decrease in compulsive behaviors, compared to 20% in the placebo group. Moreover, those on semaglutide demonstrated improved control over their consumption habits. Some participants also reported reduced dependence on other substances. Despite these promising outcomes, experts emphasize the necessity of larger clinical trials to evaluate the long-term safety and efficacy of the medication in addressing compulsive behaviors.